People: Solazyme Inc (SZYM.O)
SZYM.O on Nasdaq
10.95USD
17 May 2013
10.95USD
17 May 2013
Price Change (% chg)
$0.03 (+0.27%)
$0.03 (+0.27%)
Prev Close
$10.92
$10.92
Open
$10.98
$10.98
Day's High
$11.12
$11.12
Day's Low
$10.86
$10.86
Volume
622,923
622,923
Avg. Vol
598,236
598,236
52-wk High
$14.34
$14.34
52-wk Low
$6.45
$6.45
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Jerry Fiddler |
60 | 2004 | Independent Chairman of the Board |
Harrison Dillon |
41 | 2012 | President, Director |
Jonathan Wolfson |
41 | 2010 | Chief Executive Officer, Director |
Tyler Painter |
40 | 2007 | Chief Financial Officer |
Jean-Marc Rotsaert |
42 | 2012 | Chief Operating Officer |
Peter Licari |
48 | 2012 | Executive Vice President - Technology, Chief Technology Officer |
Paul Quinlan |
49 | 2010 | General Counsel, Corporate Secretary |
Peter Kovacs |
2013 | Director | |
Michael Arbige |
57 | 2005 | Independent Director |
Ian Clark |
51 | 2011 | Independent Director |
William Lese |
2008 | Independent Director | |
Ann Mather |
52 | 2011 | Independent Director |
Biographies
| Name | Description |
|---|---|
Jerry Fiddler |
Mr. Jerry L. Fiddler is Independent Chairman of the Board of Solazyme Inc. From 1981 to 2009 Mr. Fiddler was, at various times, the founder, Chief Executive Officer, Chairman and/or director of Wind River Systems, Inc., a publicly held software company, until it was acquired by Intel Corporation, a semiconductor company. Mr. Fiddler is the principal/CEO of Zygote Ventures, LLC, and an adjunct professor at University of California, Berkeley. He serves on a number of private company and non-profit boards. Mr. Fiddler obtained an M.S. from the University of Illinois. |
Harrison Dillon |
Dr. Harrison F. Dillon, Ph.D., is President, Director of Solazyme Inc. He is a co-founder and was Chief Executive Officer from 2003 until 2008 when he became President and Chief Technology Officer. Prior to founding Solazyme, Dr. Dillon was an associate at Kilpatrick Townsend & Stockton LLP formerly Townsend and Townsend and Crew LLP, a law firm, from 2003 to 2004. Prior to joining Kilpatrick Townsend & Stockton LLP, Dr. Dillon held a variety of positions related to intellectual property law and technology licensing at Parsons, Behle, and Latimer PLC, a law firm, and the University of Utah Research Foundation, an academic institution. Dr. Dillon obtained a J.D. from Duke University School of Law and a Ph.D. in genetics from the University of Utah. He has served as a member of the board of directors since inception. |
Jonathan Wolfson |
Mr. Jonathan S. Wolfson is Chief Executive Officer and Director of Solazyme Inc. He is a co-founder and was President and Chief Operating Officer from 2003 until 2008 when he became Chief Executive Officer. Prior to founding Solazyme, Mr. Wolfson held a variety of positions in finance, business and law, most recently that of Vice President of Finance and Business Development for 7thOnline, Inc., a supply chain software company. Immediately prior to that Mr. Wolfson was co-founder and Chief Operating Officer of InvestorTree, Inc., a financial services software company. Mr. Wolfson obtained a law degree from New York University (NYU) School of Law and an M.B.A. from NYU Stern School of Business. |
Tyler Painter |
Mr. Tyler W. Painter is Chief Financial Officer of Solazyme Inc. Prior to joining the Company, Mr. Painter served as interim Corporate Controller for PMC-Sierra (PMCS), a provider of broadband communications and internet infrastructure semiconductor solutions, from May 2007 through October 2007. From 2001 to 2007, Mr. Painter served as Vice President of Finance and Investor Relations and Corporate Treasurer for Wind River Systems, Inc., a software company. Prior to joining Wind River Systems, Inc., Mr. Painter held a variety of positions in finance at CarsDirect, Inc., an online automobile sales company, and at Gap, Inc., a retail clothing company. Mr. Painter obtained a B.S. in Business Administration/Finance from California Polytechnic State University, San Luis Obispo. |
Jean-Marc Rotsaert |
Mr. Jean-Marc Rotsaert has been appointed as Chief Operating Officer of Solazyme, Inc., effective 22 October 2012. Mr. Rotsaert most recently served as President and Chief Executive Officer of AAK, USA, a specialty vegetable fats and oils supplier, from 2009 until May 2012. Prior to joining AAK, he was an operating partner at Graham Partners, a private equity fund, from 2008 to 2010. He was Vice President, Science and Technology during 2008 at Campbell Soup Company, a convenience food product company, and was Vice President, Research and Development for Pepsico International (UK and Ireland), a food and beverage company, from 2003 through 2008. Mr. Rotsaert held various positions with the Coca-Cola Company, a beverage company, from 1992 through 2003. Mr. Rotsaert obtained a graduate degree (Polytechnicien) in Electrical Engineering from Faculté Polytechnique de Mons, Belgium. |
Peter Licari |
Dr. Peter J. Licari, Ph.D., is Executive Vice President - Technology, Chief Technology Officer of Solazyme Inc. He served as Senior Vice President, Research and Development from October 2008 through December 2010. From 1998 to 2008, Dr. Licari held various positions at Kosan Biosciences, Inc., a biopharmaceutical company. In his last position at Kosan Biosciences, Inc. he served as Senior Vice President, Manufacturing and Operations responsible for the process development and manufacturing of Kosan’s clinical compounds. From 1993 to 1996, Dr. Licari served as the Director of Vaccine Manufacturing and Development at Massachusetts Biologic Laboratories, a part of the University of Massachusetts, an academic institution. Prior to joining Massachusetts Biologic Laboratories, Dr. Licari had a variety of research positions at BASF Bioresearch Corporation, a biopharmaceutical company, and Merck & Co., Inc., a pharmaceutical company. Dr. Licari obtained his Ph.D. in Chemical Engineering from the California Institute of Technology and obtained a M.B.A. from Pepperdine University. |
Paul Quinlan |
Mr. Paul T. Quinlan is General Counsel and Corporate Secretary of Solazyme Inc. He has served as General Counsel since May 2010 and as Secretary since June 2010. From 2005 to 2010 Mr. Quinlan was General Counsel at Metabolex, Inc., a biopharmaceutical company. In this position, he was responsible for overseeing the legal affairs of Metabolex, Inc. From 2000 to 2005, Mr. Quinlan held various positions in the legal department at Maxygen, Inc., a biopharmaceutical company, most recently that of Chief Corporate Securities Counsel. Prior to joining Maxygen, Inc., Mr. Quinlan was an associate at Cooley LLP, a law firm, and Cravath, Swaine & Moore LLP, a law firm. Mr. Quinlan obtained a law degree from Columbia University Law School and a M.Sc. in Medical Biophysics from the University of Toronto. |
Peter Kovacs |
Mr. Peter Kovacs is appointed as the Director of Solazyme, Inc. Mr. Kovacs has been a consultant, providing business consulting services, to a variety of companies since 1997. He has been a consultant to the Company since 2007. From 1994 until his retirement in 1997, Mr. Kovacs served as President and CEO of the NutraSweet Kelco Company, a nutritional and specialty chemicals company. From 1993 to 1994 he was President and CEO of the Kelco Company, a specialty chemicals company. Mr. Kovacs was employed by Kelco in various capacities from 1967, through his appointment as President and CEO in 1993, until Kelco’s acquisition by Monsanto in 1994. Mr. Kovacs obtained a B.S. in chemistry from San Diego State University. |
Michael Arbige |
Dr. Michael V. Arbige, Ph.D., is Independent Director of Solazyme Inc. From 1990 to 2011, Dr. Arbige held a variety of positions at Genencor, most recently as its Executive Vice President of Research and Development, a position he held from 2009 to 2011 . He is responsible for all activities associated with managing and driving the research and development activities for the division. Dr. Arbige obtained his Ph.D. in Microbial Physiology and Genetics in 1982 from the University of New Hampshire. |
Ian Clark |
Mr. Ian T. Clark is Independent Director of Solazyme Inc. Mr. Clark currently serves as chief executive officer of Genentech, Inc., a member of the Roche Group, and head of North American Commercial Operations. He was appointed to this role in January 2010. Mr. Clark also leads the Genentech executive committee and is a member of the Genentech board of directors. Mr. Clark joined Genentech in 2003 as senior vice president and general manager, BioOncology. In August 2005 he was named senior vice president, Commercial Operations and became a member of the executive committee, and in January 2006, he was named executive vice president, Commercial Operations. In April 2009, he was named head of Global Product Strategy and chief marketing officer. Prior to joining Genentech, Mr. Clark served as president of Novartis Canada, overseeing all of the company’s country operations. Before assuming his post in Canada, Mr. Clark served as chief operating officer for Novartis United Kingdom. Prior to joining Novartis in 1999, Mr. Clark worked in vice presidential roles in sales and marketing for Sanofi (Aventis) and Ivax in the United Kingdom and Eastern Europe. Mr. Clark has served on the board of the Biotechnology Industry Organization (BIO) Industry Association since 2009, is an advisor to the Institute of Life Sciences at Southampton University in the United Kingdom, and is a member of the Federal Reserve Bank of San Francisco’s Economic Advisory Council. Mr. Clark received a Bachelor of Science degree in biological sciences from Southampton University in the United Kingdom. |
William Lese |
Mr. William D. Lese is Independent Director of Solazyme Inc. Mr. Lese co-founded and since 2002 has served as a managing partner of Braemar Energy Ventures, LP, a venture capital management company, focused exclusively on investing in early to mid-stage energy technology companies predominantly located in the United States and Canada. Mr. Lese holds a B.A. in Physics and a M.Sc. in Energy Sciences from New York University. |
Ann Mather |
Ms. Ann Mather is Independent Director of Solazyme Inc. Ms. Mather has been a member of the board of directors of Google Inc., an online search provider, since November 2005, and serves as chair of its audit committee; Glu Mobile Inc., a publisher of mobile games, since September 2005, and serves as chair of its Audit Committee; MGM Holdings Inc., a motion picture and television production and distribution company, since December 2010, and serves on its Compensation Committee; MoneyGram International, a global payment services company, since May 2010; and Netflix, Inc., an internet subscription service for movies and television shows, since July 2010, and serves on its Audit Committee. Ms. Mather has been an Independent Trustee to the Dodge and Cox funds Board of Trustees since May 2011. Ms. Mather was previously a director of Central European Media Enterprises Group, a developer and operator of national commercial television channels and stations in Central and Eastern Europe; Zappos.com, Inc., a privately held, online retailer, until it was acquired by Amazon.com, Inc. in 2009; and Shopping.com, Inc., a price comparison web site, until it was acquired by eBay Inc. in 2005. From 1999 to 2004, Ms. Mather was Executive Vice President and Chief Financial Officer of Pixar, a computer animation studio. Prior to her service at Pixar, Ms. Mather was Executive Vice President and Chief Financial Officer at Village Roadshow Pictures, the film production division of Village Roadshow Limited. Ms. Mather holds a Master of Arts degree from Cambridge University and is a chartered accountant. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Jerry Fiddler |
-- |
Harrison Dillon |
1,114,840 |
Jonathan Wolfson |
1,706,770 |
Tyler Painter |
888,740 |
Jean-Marc Rotsaert |
-- |
Peter Licari |
886,189 |
Paul Quinlan |
784,974 |
Peter Kovacs |
-- |
Michael Arbige |
-- |
Ian Clark |
-- |
William Lese |
-- |
Ann Mather |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Jerry Fiddler |
0 | 0 |
Harrison Dillon |
25,000 | 57,650 |
Jonathan Wolfson |
25,000 | 57,650 |
Tyler Painter |
0 | 0 |
Jean-Marc Rotsaert |
0 | 0 |
Peter Licari |
94,687 | 0 |
Paul Quinlan |
0 | 0 |
Peter Kovacs |
0 | 0 |
Michael Arbige |
0 | 0 |
Ian Clark |
0 | 0 |
William Lese |
0 | 0 |
Ann Mather |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PAINTER TYLER W |
10,000 | $10.28 |
LICARI PETER J |
18,500 | $0.86 |
PAINTER TYLER W |
10,000 | $10.00 |
LICARI PETER J |
9,000 | $1.01 |
DILLON HARRISON F |
27,000 | $10.03 |
LICARI PETER J |
35,000 | $10.00 |
QUINLAN PAUL T |
21,000 | $2.35 |
QUINLAN PAUL T |
21,000 | $10.00 |
MILLER DANIEL H |
9,500 | $9.00 |
MILLER DANIEL H |
9,500 | $9.00 |
WOLFSON JONATHAN S |
25,000 | $8.00 |
STRAUCH ROGER A |
5,000 | $7.52 |
STRAUCH ROGER A |
5,000 | $7.55 |
WOLFSON JONATHAN S |
25,000 | $8.27 |
DILLON HARRISON F |
13,500 | $8.79 |
DILLON HARRISON F |
13,500 | $8.99 |
PAINTER TYLER W |
10,000 | $9.10 |
WOLFSON JONATHAN S |
25,000 | $9.33 |
MILLER DANIEL H |
9,500 | $9.00 |
MILLER DANIEL H |
7,478 | $0.00 |
MILLER DANIEL H |
670,613 | $0.00 |
MILLER DANIEL H |
145,463 | $0.00 |
MILLER DANIEL H |
12,407 | $0.00 |
MILLER DANIEL H |
12,355 | $0.00 |
MILLER DANIEL H |
167,435 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
